Yungjin Pharm Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top 15 shareholders own 54.71% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
52.5%	KT&G Corporation	95,928,655	₩202.4b	0%	no data
1.59%	The Vanguard Group, Inc.	2,908,313	₩6.1b	0.98%	no data
0.29%	Dimensional Fund Advisors LP	521,338	₩1.1b	0%	no data
0.13%	Mirae Asset Global Investments Co., Ltd.	229,045	₩483.3m	0%	no data
0.075%	Charles Schwab Investment Management, Inc.	136,500	₩288.0m	0%	no data
0.065%	State Street Global Advisors, Inc.	119,600	₩252.3m	-0.47%	no data
0.061%	Samsung Asset Management Company, Ltd.	112,202	₩236.8m	0%	no data
0.045%	Norges Bank Investment Management	83,048	₩175.2m	0%	no data
0.0068%	Yungjin Pharmaceutical Co., Ltd.,ESOP	12,517	₩26.4m	0%	no data
0.0057%	KB Asset Management Co., Ltd.	10,416	₩22.0m	0%	no data
0.00076%	Invesco Capital Management LLC	1,384	₩2.9m	0%	no data
0.00046%	American Century Investment Management Inc	848	₩1.8m	0%	no data
0.00038%	NH-Amundi Asset Management	688	₩1.5m	0%	no data
0.00034%	Korea Investment Management Co., Ltd.	615	₩1.3m	0%	no data
0.00012%	Consus Asset Management Co. Ltd.	218	₩463.1k	0%	0.01%